JNJ

173.56

+1.32%↑

ABBV

198.07

-0.35%↓

AZN

73.59

-1.31%↓

ABT

134.42

+1.78%↑

UNH

250.68

+2.57%↑

JNJ

173.56

+1.32%↑

ABBV

198.07

-0.35%↓

AZN

73.59

-1.31%↓

ABT

134.42

+1.78%↑

UNH

250.68

+2.57%↑

JNJ

173.56

+1.32%↑

ABBV

198.07

-0.35%↓

AZN

73.59

-1.31%↓

ABT

134.42

+1.78%↑

UNH

250.68

+2.57%↑

JNJ

173.56

+1.32%↑

ABBV

198.07

-0.35%↓

AZN

73.59

-1.31%↓

ABT

134.42

+1.78%↑

UNH

250.68

+2.57%↑

JNJ

173.56

+1.32%↑

ABBV

198.07

-0.35%↓

AZN

73.59

-1.31%↓

ABT

134.42

+1.78%↑

UNH

250.68

+2.57%↑

Search

Novartis AG

Cerrado

116.79 0.8

Resumen

Variación precio

24h

Actual

Mínimo

116.52

Máximo

116.9

Métricas clave

By Trading Economics

Ingresos

418M

4B

Ventas

660M

14B

P/B

Media del Sector

16.809

34.393

BPA

2.42

Rentabilidad por dividendo

3.46

Margen de beneficio

28.18

Empleados

75,883

EBITDA

-5.8B

4.9M

Recomendaciones

By TipRanks

Recomendaciones

Neutral

Estimación a 12 meses

+5.92% upside

Dividendos

By Dow Jones

Rentabilidad por dividendo

Media del Sector

3.46%

2.54%

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

-11B

228B

Apertura anterior

115.99

Cierre anterior

116.79

Puntuación técnica

By Trading Central

Confianza

Bearish Evidence

Novartis AG Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

7 ago 2025, 05:47 UTC

Adquisiciones, fusiones, absorciones

Novartis Makes Takeover Approach for Avidity Biosciences, FT Says, Citing Sources

17 jul 2025, 14:26 UTC

Ganancias

Novartis Launches Buyback of Up to $10 Billion, Lifts Profit Outlook -- 2nd Update

17 jul 2025, 06:49 UTC

Ganancias

Novartis Launches Buyback of Up to $10 Billion, Lifts Profit Outlook -- Update

17 jul 2025, 05:41 UTC

Ganancias

Novartis Lifts Profit Outlook After Growth in Sales, Earnings

8 ago 2025, 11:26 UTC

Charlas de Mercado

Novartis Is Getting Closer to Midterm Targets -- Market Talk

8 ago 2025, 11:07 UTC

Charlas de Mercado
Adquisiciones, fusiones, absorciones

Novartis Has Room to Accelerate Dealmaking -- Market Talk

8 ago 2025, 10:51 UTC

Charlas de Mercado
Adquisiciones, fusiones, absorciones

Novartis's Midterm Prospects Look Better Than Roche's -- Market Talk

5 ago 2025, 10:40 UTC

Charlas de Mercado

Roche, Novartis Face Limited Tariff Headwinds for Now -- Market Talk

17 jul 2025, 11:36 UTC

Charlas de Mercado

Novartis CEO Urges Europe to Reform Drug-Pricing System -- Market Talk

17 jul 2025, 11:26 UTC

Charlas de Mercado

Novartis CEO Confident on Midterm Plan to Mitigate U.S. Tariff Hit -- Market Talk

17 jul 2025, 07:14 UTC

Charlas de Mercado

Retirement of Well-Regarded Executive a Loss for Novartis -- Market Talk

17 jul 2025, 07:02 UTC

Charlas de Mercado
Ganancias

Novartis's Results Look Impressive -- Market Talk

17 jul 2025, 05:09 UTC

Ganancias

Novartis 2Q Sales Grew 11% at Constant Currency

17 jul 2025, 05:08 UTC

Ganancias

Novartis: Kirsch Will Continue as CFO, Member of Executive Committee Until March 2026

17 jul 2025, 05:06 UTC

Ganancias

Novartis: Mehta's Appointment Is Effective March 2026

17 jul 2025, 05:05 UTC

Ganancias

Novartis: Harry Kirsch Retires After 22 Years With Company

17 jul 2025, 05:05 UTC

Ganancias

Novartis Names Mukul Mehta as CFO

17 jul 2025, 05:04 UTC

Ganancias

Analysts Saw Novartis 2Q Net Profit at $3.815B

17 jul 2025, 05:04 UTC

Ganancias

Analysts Saw Novartis 2Q Core Operating Profit at $5.75B

17 jul 2025, 05:04 UTC

Ganancias

Analysts Saw Novartis 2Q Sales at $14.17B

17 jul 2025, 05:04 UTC

Ganancias

Novartis 2Q Core Operating Profit $5.925B

17 jul 2025, 05:04 UTC

Ganancias

Novartis 2Q Oper Pft $4.86B

17 jul 2025, 05:03 UTC

Ganancias

Novartis 2Q Sales $14.05B

17 jul 2025, 05:01 UTC

Ganancias

Novartis: Buyback to Be Completed by End of 2027

17 jul 2025, 05:01 UTC

Ganancias

Novartis Starting Buyback of Up to $10B

17 jul 2025, 05:01 UTC

Ganancias

Novartis Backs 2025 Sales View

17 jul 2025, 05:01 UTC

Ganancias

Novartis Had Guided for Low Double-Digit Growth in Core Operating Profit at Constant Currency

17 jul 2025, 05:01 UTC

Ganancias

Novartis Expects 2025 Core Operating Profit to Grow by Low Teens at Constant Currency

17 jul 2025, 05:00 UTC

Ganancias

Novartis Raises 2025 Earnings View

17 jul 2025, 05:00 UTC

Ganancias

Novartis AG 2Q Adj EPS $2.42

Comparación entre iguales

Cambio de precio

Novartis AG Esperado

Precio Objetivo

By TipRanks

5.92% repunte

Estimación a 12 meses

Media 122.78 USD  5.92%

Máximo 137.561 USD

Mínimo 108 USD

De acuerdo con 3 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Novartis AG Dist en los últimos 3 meses.

Consenso

By TipRanks

Neutral

3 ratings

0

Comprar

3

Mantener

0

Vender

Puntuación técnica

By Trading Central

N/A / 112.63Soporte y Resistencia

Corto Plazo

Bearish Evidence

Medio plazo

Weak Bullish Evidence

Largo Plazo

Strong Bullish Evidence

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Novartis AG

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. The company also provides Pluvicto, lutetium Lu 177 vipivotide tetraxetan, indicated for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer; and Lutathera, lutetium Lu 177 dotatate, a prescription medicine used to treat adults and children aged 12 years and older with gastroenteropancreatic neuroendocrine tumors. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology. The company has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol; and Dawn Health for the development and commercialization of Ekiva, a digital solution designed for people living with Paroxysmal Nocturnal Hemoglobinuria. It also has a research collaboration and license agreement with Schrödinger, Inc. to identify and develop various therapeutic candidates; and a strategic collaboration with Vyriad, Inc. for the discovery and development for vivo chimeric antigen receptor T-cell therapies. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.